抗高血压药—血管紧张素Ⅱ受体阻断剂依贝沙坦(Irbesartan)

Irbesartan-antihypertensive Drug of Angiotension Ⅱ Receptor Antagonist

在高血压的发病机制中肾素-血管紧张素系统（RAS）起着重要的作用，血管紧张素转换酶（ACE）抑制剂通过抑制此系统减少了使血管收缩的血管紧张素Ⅱ的产生，但同时又可形成一些病人不能耐受的如咳嗽的药物不良反应。血管紧张素-Ⅱ受体拮抗剂是新一类的降压药，其直接阻滞血管紧张素-Ⅱ的ATI受体，降压作用强，且药物不良反应低，病人耐受性好。本文对此类药物中的新品种依贝沙坦（Irbesaftan）的临床前基础研究、健康志愿者体内进行的药效动力学和药代动力学研究，以及对轻、中度高血压的临床疗效和安全性进行了较全面的综述。

Renin-Angiotensin-System(RAS) exhibits a key role in the pathogenesis ofhypertension. Angiotensin converting enzyme(ACE) inhibitor reduced the formation ofangiotension-Ⅱ of RAS, and it also induces some adverse effects such as coughing, whichthe patient could not tolerate. Angiotensin-Ⅱ receptor antagonist is a new kind ofantihypertensive drug. It directly inhibited angiotension Ⅱ AT1 receptor, and itsantihypertension was effective and safe, and it had lower adverse effects. In this article, forone of the new angiotensin-Ⅱ-irbesartan drugs, we summarized the pre-clinical-basic study,the pharmacodynamics and pharmacokinetics study in the volunteers, and the effect andsafety for mild, and moderate hypertension.